Immunotherapy, an innovative approach to cancer treatment, is rapidly evolving as a frontline strategy in the fight against a variety of malignancies. This article aims to provide physicians with a comprehensive understanding of the key aspects of immunotherapy, from its basic principles to its clinical applications.
Immunotherapy, also known as biological therapy, is a type of cancer treatment designed to boost the body's natural defenses to fight cancer. It uses substances made by the body or in a laboratory to improve or restore immune system function. The key to immunotherapy lies in its ability to harness the power of the patient's immune system, enabling it to detect and target cancer cells more effectively.
There are several types of immunotherapy, including monoclonal antibodies, immune checkpoint inhibitors, cancer vaccines, and CAR T-cell therapy. Monoclonal antibodies are designed to bind to specific targets on cancer cells, while immune checkpoint inhibitors help the immune system recognize and attack cancer cells. Cancer vaccines work by triggering the immune system to attack specific diseases, and CAR T-cell therapy involves modifying T cells to enhance their ability to fight cancer.
Immunotherapy has shown promising results in treating various types of cancer, such as melanoma, lung, kidney, bladder, and head and neck cancers. However, not all patients respond to immunotherapy, and it can cause side effects, including inflammation and immune-related adverse events. Determining which patients will benefit from immunotherapy remains a significant challenge in the field.
Immunotherapy represents a groundbreaking shift in cancer treatment, offering new hope to patients who have previously exhausted all other options. As our understanding of the immune system's role in cancer continues to evolve, it's crucial for physicians to stay abreast of the latest advancements and applications of immunotherapy to provide the best possible care for their patients.
1.
Research discovery halts childhood brain tumor before it forms
2.
Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.
3.
'CDC Must Be Investigated'; David Lynch, Bob Uecker Die; Nasal Epinephrine Warning
4.
Increasing Access to Prostate Cancer Drugs; Reducing Toxic Emissions; FTC Files a 'Charity' Suit.
5.
Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers
1.
Beyond the Blinders: A Review of Targeted Therapeutic Strategies for Triple-Negative Breast Cancer in 2025
2.
AI-Based Cancer Follow-Up Monitoring: Transforming Survivorship Care through Intelligent Surveillance
3.
Preventing Sarcopenia During Cancer Treatment
4.
Guidance for Managing Complex Anticoagulation
5.
Unlocking the Potential of Sarclisa: A New Hope for Cancer Treatment
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on Standard V/S High Risk Myeloma Treatment
2.
Navigating the Complexities of Ph Negative ALL - Part XIV
3.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
4.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation